作者: R Henschler , W Brugger , T Luft , T Frey , R Mertelsmann
DOI: 10.1182/BLOOD.V84.9.2898.2898
关键词:
摘要: CD34(+)-selected hematopoietic progenitor cells are being increasingly used for autotransplantation, and recent evidence indicates that these can be expanded ex vivo. Of 15 patients with solid tumors undergoing a phase I/II clinical trial using peripheral blood (PBPCs) after high-dose chemotherapy, we analyzed the frequency of long-term culture-initiating (LTCIC) as measure transplantation potential before vivo expansion CD34+ cells. PBPCs were mobilized by combination chemotherapy granulocyte colony-stimulating factor (G-CSF). The original unseparated leukapheresis preparations, CD34(+)-enriched transplants, well nonabsorbed fractions eluting from CD34 immunoaffinity columns (Ceprate; CellPro, Bothell, WA) monitored their capacity to repopulate irradiated allogeneic stroma in human bone marrow cultures. We found preservation more than three quarters fully functional LTCIC fractions. Quantitation limiting dilution analysis showed 53-fold enrichment 1/9,075 an incidence 1/169 Thus, single apheresis, it was possible harvest median 1.65 x 10(4) per kg body weight (range, 0.71 3.72). In addition, six patients, large-scale expansions performed five-factor cytokine consisting stem cell (SCF), interleukin-1 (IL-1), IL-3, IL-6, erythropoietin (EPO), previously shown expand committed preserved, but not during culture period. Optimization growth requirements assays estimation indicated SCF, IL-1, EPO together autologous plasma most reliable securing both high yield and, at same time, optimal LTCIC. Our data suggest vivo-expanded might able allow reconstitution hematopoiesis.